|
1
|
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
|
J Hepatol
|
2008
|
3.50
|
|
2
|
euHCVdb: the European hepatitis C virus database.
|
Nucleic Acids Res
|
2006
|
2.41
|
|
3
|
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
|
Clin Gastroenterol Hepatol
|
2007
|
2.08
|
|
4
|
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study.
|
Hepatology
|
2002
|
1.94
|
|
5
|
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
|
J Hepatol
|
2003
|
1.87
|
|
6
|
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.
|
Gastroenterology
|
2011
|
1.85
|
|
7
|
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
|
Hepatology
|
2005
|
1.80
|
|
8
|
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.
|
J Virol
|
2003
|
1.79
|
|
9
|
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.
|
J Hepatol
|
2008
|
1.63
|
|
10
|
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease.
|
J Hepatol
|
2010
|
1.57
|
|
11
|
Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C.
|
Hepatology
|
2011
|
1.49
|
|
12
|
Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.47
|
|
13
|
[Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients].
|
Gastroenterol Clin Biol
|
2003
|
1.40
|
|
14
|
Hepatitis C screening practices among private practitioners: impact of an information campaign.
|
Gastroenterol Clin Biol
|
2005
|
1.40
|
|
15
|
Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins.
|
J Gen Virol
|
2006
|
1.39
|
|
16
|
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.
|
J Hepatol
|
2005
|
1.38
|
|
17
|
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.
|
Clin Gastroenterol Hepatol
|
2010
|
1.35
|
|
18
|
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma.
|
J Hepatol
|
2005
|
1.33
|
|
19
|
Origin and characterization of a human bipotent liver progenitor cell line.
|
Gastroenterology
|
2004
|
1.32
|
|
20
|
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
|
J Hepatol
|
2006
|
1.27
|
|
21
|
Progression to cirrhosis in hepatitis C patients: an age-dependent process.
|
Liver Int
|
2007
|
1.15
|
|
22
|
Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.
|
J Virol
|
2004
|
1.14
|
|
23
|
Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.
|
PLoS One
|
2011
|
1.11
|
|
24
|
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
|
Gastroenterology
|
2006
|
1.10
|
|
25
|
Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
|
Hepatology
|
2002
|
1.06
|
|
26
|
A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.
|
Hepatology
|
2004
|
1.02
|
|
27
|
Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.
|
J Hepatol
|
2003
|
1.02
|
|
28
|
Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.
|
J Gen Virol
|
2006
|
1.01
|
|
29
|
Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC).
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.00
|
|
30
|
Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
|
Antimicrob Agents Chemother
|
2003
|
1.00
|
|
31
|
Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA.
|
Antimicrob Agents Chemother
|
2008
|
0.95
|
|
32
|
Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope.
|
J Biol Chem
|
2003
|
0.94
|
|
33
|
Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.
|
Antimicrob Agents Chemother
|
2002
|
0.94
|
|
34
|
Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B.
|
J Med Virol
|
2009
|
0.93
|
|
35
|
Enveloped particles in the serum of chronic hepatitis C patients.
|
Virology
|
2005
|
0.91
|
|
36
|
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
|
J Gen Virol
|
2007
|
0.90
|
|
37
|
Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
|
J Med Virol
|
2009
|
0.89
|
|
38
|
Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age.
|
J Acquir Immune Defic Syndr
|
2002
|
0.88
|
|
39
|
Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand.
|
Hepat Res Treat
|
2011
|
0.88
|
|
40
|
Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
|
Antivir Ther
|
2008
|
0.87
|
|
41
|
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
|
Dig Liver Dis
|
2011
|
0.86
|
|
42
|
Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
|
J Hepatol
|
2005
|
0.85
|
|
43
|
Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.
|
Hepatology
|
2013
|
0.85
|
|
44
|
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection.
|
J Hepatol
|
2009
|
0.85
|
|
45
|
Analysis of B-lymphocyte differentiation in patients infected with hepatitis C virus.
|
J Med Virol
|
2004
|
0.84
|
|
46
|
Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus.
|
Hepatology
|
2010
|
0.84
|
|
47
|
A new viral agent, SEN virus (SENV), has been detected in patients from several countries: the pathogenic role of SENV in coinfections with hepatitis B virus or hepatitis C virus should be investigated.
|
J Infect Dis
|
2002
|
0.84
|
|
48
|
Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA).
|
J Virol Methods
|
2013
|
0.82
|
|
49
|
The recent increase of syphilis cases in Lyon University hospitals Is mainly observed in HIV-infected patients: descriptive data from a laboratory-based surveillance system.
|
J Acquir Immune Defic Syndr
|
2003
|
0.82
|
|
50
|
Long-term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes.
|
Hepatology
|
2011
|
0.81
|
|
51
|
HDV genotypes in the Western Brazilian Amazon region: A preliminary report.
|
Am J Trop Med Hyg
|
2006
|
0.81
|
|
52
|
Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France.
|
Eur J Gastroenterol Hepatol
|
2004
|
0.80
|
|
53
|
[Imatinib mesylate-induced acute cytolytic hepatitis].
|
Gastroenterol Clin Biol
|
2004
|
0.80
|
|
54
|
Evolution of Hepatitis B and C serum markers: a still challenging issue.
|
Liver Int
|
2011
|
0.79
|
|
55
|
Effects of co-infection with hepatitis C virus and GB virus C on CD4 cell count and HIV-RNA level among HIV-infected patients treated with highly active antiretroviral therapy.
|
AIDS
|
2002
|
0.79
|
|
56
|
Experimental transfection of Macaca sylvanus with cloned human hepatitis B virus.
|
J Gen Virol
|
2002
|
0.79
|
|
57
|
Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody.
|
J Med Virol
|
2009
|
0.78
|
|
58
|
Latent hepatitis B virus (HBV) infection and HBV DNA integration is associated with further transformation of hepatoma cells in vitro.
|
ALTEX
|
2003
|
0.78
|
|
59
|
Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
|
Antimicrob Agents Chemother
|
2006
|
0.78
|
|
60
|
What is really ongoing during occult HBV reactivation?
|
Hepatology
|
2006
|
0.78
|
|
61
|
Study of HBV replication capacity in relation to sequence variation in the precore and core promoter regions.
|
Methods Mol Med
|
2004
|
0.77
|
|
62
|
Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.
|
Microbes Infect
|
2006
|
0.76
|
|
63
|
Characterization of the double-stranded RNA responses in human liver progenitor cells.
|
Biochem Biophys Res Commun
|
2008
|
0.76
|
|
64
|
Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.
|
Antivir Ther
|
2013
|
0.76
|
|
65
|
Diversity of hepatocellular carcinoma clones bearing hematopoietic malignancies-related chromosomal translocation.
|
J Cell Biochem
|
2014
|
0.75
|
|
66
|
[Autoimmunization induced by interferon alpha therapy in chronic hepatitis C].
|
Gastroenterol Clin Biol
|
2004
|
0.75
|
|
67
|
Expression of E1E2 on hepatitis C RNA-containing particles released from primary cultured human hepatocytes derived from infected cirrhotic livers.
|
Intervirology
|
2010
|
0.75
|
|
68
|
[In vitro hepatitis C. Elimination of lipoproteins associated with cells: an important stage to obtain an efficient infection of human hepatocytes by the hepatitis C virus].
|
Rev Med Suisse Romande
|
2002
|
0.75
|
|
69
|
Factors associated with the time elapsed between initial detection of HIV antibodies and first contact for healthcare in HIV seroconverters of the Lyon University Hospitals.
|
J Acquir Immune Defic Syndr
|
2002
|
0.75
|
|
70
|
Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial.
|
Therapie
|
2012
|
0.75
|